Advertisement

Topics

Jiangsu Hengrui Medicine Co., Ltd. Company Profile

11:10 EST 23rd January 2019 | BioPortfolio

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $1.6 billion in 2016. Hengrui is devoted to empowering healthier lives through research, and currently has 3 programs under China NDA as well as 21 new molecular entities in clinical development in China, U.S., and Australia, across oncology, anesthesiology & pain management, immunology & inflammation, and cardiovascular & metabolic diseases.


News Articles [687 Associated News Articles listed on BioPortfolio]

Jiangsu Hengrui Forms Global Clinical Collaboration with LSK BioPharma

Jiangsu Hengrui Medicine and LSK BioPharma of Salt Lake City announced a global test that combines Hengrui's PD-1 candidate with LSKB's rivoceranib, a VEGFR-2 inhibitor, as a treatment for hepatocellu...

Jiangsu Hengrui's breast cancer drug conditionally approved in China

China's State Drug Administration granted conditional approval to Jiangsu Hengrui Medicine's priority review-tagged pyrotinib -More- 

Sedation – Pipeline Review, H2 2018 Featuring Drawbridge Pharmaceuticals, Jiangsu Hengrui Medicine, Jiangsu Nhwa Pharmaceutical, Paion, Primex Pharmaceuticals & Therakind – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Sedation – Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. Sedation – Pipeline Revie...

Hengrui Medicine Approved to Market Novel HER2 Cancer Drug in China

Jiangsu Hengrui Medicine was awarded China approval of a novel treatment for HER2-positive cancer as a second-line therapy. Pyrotinib, a dual EGFR/HER2 dual tyrosine kinase inhibitor, was conditionall...

Reistone of Shanghai Approved for US Phase II Trial of UC Treatment

Reistone Biopharma, a Shanghai startup, announced FDA approval to start a US Phase II clinical trial of a Janus Kinase 1 inhibitor (JAK1) in patients with ulcerative colitis.  Reistone said the a...

LSKB, Hengrui Enter Clinical Collaboration

To evaluate the safety & efficacy of LSKB's rivoceranib, known as apatinib or Aitan® in China with Hengrui's camrelizumab

Jiangsu Hengrui Medicine Co Ltd 600276 Financial and Strategic SWOT Analysis Review [Report Updated: 29082018] Prices from USD $125

Jiangsu Hengrui Medicine Co Ltd 600276 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been co...

Jiangsu Hengrui Medicine Co Ltd 600276 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 07092018] Prices from USD $250

SummaryJiangsu Hengrui Medicine Co Ltd Jiangsu Hengrui is a biopharmaceutical company that focuses on the research, development, manufacture and distribution of novel pharmaceutical products. Its prod...

Drugs and Medications [9 Associated Drugs and Medications listed on BioPortfolio]

Letrozole [Jiangsu Hengrui Medicine Co., Ltd.]

These highlights do not include all the information needed to use LETROZOLE TABLETS safely and effectively. See full prescribing information for LETROZOLE TABLETS. LETROZOLE tablets, for oral use Init...

Docetaxel [Jiangsu Hengrui Medicine Co., Ltd.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION. DOCETAXEL injection (concentrate...

Dexmedetomidine hydrochloride [Jiangsu Hengrui Medicine Co., Ltd.]

These highlights do not include all the information needed to use DEXMEDETOMIDINE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE INJECTION. DEXMEDETOMIDINE inje...

Docetaxel [Jiangsu Hengrui Medicine Co., Ltd.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION. DOCETAXEL Injection, for intrave...

Cisatracurium besylate [Jiangsu Hengrui Medicine Co., Ltd.]

These highlights do not include all the information needed to use CISATRACURIUM BESYLATE INJECTION safely and effectively. See full prescribing information for CISATRACURIUM BESYLATE INJECTION. CISATR...

PubMed Articles [1218 Associated PubMed Articles listed on BioPortfolio]

Prevalence of overweight and obesity among primary school-aged children in Jiangsu Province, China, 2014-2017.

Data was limited on prevalence of overweight and obesity among primary school-aged children in Jiangsu Province. We aimed to present the current situation of obesity in Jiangsu Province and explore th...

Current status of chronic filariasis in Jiangsu Province.

To understand the current status of chronic filariasis patients in Jiangsu Province so as to provide basic data for following-up care for them.

Assessment of schistosomiasis elimination in Changzhou City, Jiangsu Province.

To assess the state of schistosomiasis elimination in 6 districts of Changzhou City, Jiangsu Province, so as to provide the evidence for the formulation of consolidation measures.

Disease burden of patients with advanced schistosomiasis in Jiangsu Province.

To understand the disease burden of patients with advanced schistosomiasis in Jiangsu Province.

Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China.

Heroin users are vulnerable and represent a highly-infected reservoir for hepatitis C virus (HCV) infection. This study investigated HCV prevalence and genotypes distribution among heroin users who re...

Clinical Trials [1434 Associated Clinical Trials listed on BioPortfolio]

Real-world Daptomycin Use in Chinese ICUs

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, htt...

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

SHR1459 is a selective small molecule BTK inhibitor developed by Jiangsu Hengrui medicine Limited, by inhibiting the phosphorylation of BTK and down regulation of BCR signal transduction p...

Apatinib for Advanced Lung Squmamous Carcinoma

In order to search for effective and low toxicity anti-tumor angiogenesis drugs, jiangsu hengrui pharmaceutical co., ltd. developed the high-efficiency VEGFR2 tyrosine kinase inhibitor apa...

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Hepatocellular carcinoma (HCC) is one of the lethal human cancers worldwide and its incidence matches mortality, reflecting the poor prognosis of this disease. The surgical resection rate ...

Virtual Lifestyle Medicine Comparative Effectiveness Research

This study evaluates the effectiveness of two online Lifestyle Medicine programs. Participants will be randomized by residence, urban vs. rural, into one of two Lifestyle Medicine programs...

Companies [1076 Associated Companies listed on BioPortfolio]

Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $1.6 billion in 2016. Hengrui is devot...

China National Chemical Construction Jiangsu Company

China National Chemical Construction Jiangsu Company was established in January, 1992. It has independent corporate status and has the right to do foreign trade directly. It has one pesticide manufact...

Jiangsu Aolunda High-Tech. Industry Co., Ltd.

JIANGSU AOLUNDA HIGH-TECH., INDUSTRY CO.,LTD adjoinsthe Asian-Pacific banking centre of Shanghai, located in the Changjiang Delta of economic prosperity, it lies in the southeast of Jiangsu and border...

JIANGSU GUOTAI INTERNATIONAL GROUP

Jiangsu Guotai International Group is a complex group which covers international trade of textile, light industry, hardware, chemicals, minmetals, etc. Its department 3, specialized in hardware tradin...

SINOCHEM JIANGSU SUZHOU I/E CORP.

SINOCHEM JIANGSU SUZHOU I/E CORP. ESTABLISHED IN 1988, IS A SUBSIDIARY OF SINOCHEM AND A STATE-OWNED FOREIGH TRADE ENTERPRISE AUTHORISED BY THE CHINESE MINISTRY OF FOREIGH TRADE AND ECONOMIC C...

More Information about "Jiangsu Hengrui Medicine Co., Ltd." on BioPortfolio

We have published hundreds of Jiangsu Hengrui Medicine Co., Ltd. news stories on BioPortfolio along with dozens of Jiangsu Hengrui Medicine Co., Ltd. Clinical Trials and PubMed Articles about Jiangsu Hengrui Medicine Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Jiangsu Hengrui Medicine Co., Ltd. Companies in our database. You can also find out about relevant Jiangsu Hengrui Medicine Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record